Angus de Wilton

Angus de Wilton

Auto-generated profile, based on publicly available information

Angus de Wilton

Global Health and Ageing Research Unit, Bristol Medical School, University of Bristol , Bristol

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
AWAngus De Wilton
Angus De Wilton
LNLaura E. Nabarro
Laura E. Nabarro
GGGauri S. Godbole
Gauri S. Godbole
PCPeter L. Chiodini
Peter L. Chiodini
ABAileen Elizabeth Boyd
Aileen Elizabeth Boyd
KWKatherine Woods
Katherine Woods

11 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AWAngus de Wilton
Angus de Wilton
DADinesh Aggarwal
Dinesh Aggarwal
HJHans Rolf Jäger
Hans Rolf Jäger
HMHadi Manji
Hadi Manji
PCPeter L. Chiodini
Peter L. Chiodini
Background: Neuroschistosomiasis is a severe complication of schistosomiasis, triggered by the local immune reaction to egg deposition, with spinal cord involvement the most well recognised form. Early treatment with praziquantel and high dose steroids leads to a reduction of neurological sequelae. The rarity of this condition in returning travellers to high income countries can result in delayed diagnosis and treatment. We aimed to evaluate the diagnosis and management of neuroschistosomiasis in a UK national referral centre. Materials/Methods: A retrospective review of confirmed clinical cases of spinal schistosomiasis referred to the Hospital for Tropical Diseases, UK, between January 2016 and January 2020 was undertaken. Electronic referral records were interrogated and patient demographic, clinical, laboratory, and radiological data collected. Results: Four cases of neuroschistosomiasis were identified. The median age at diagnosis was 28 (range 21 to 50) with three male patients. All patients had epidemiological risk factors for schistosomiasis based on travel history and freshwater exposure; two in Uganda (River Nile), one in Malawi and one in Nigeria. All patients presented with features of transverse myelitis including back pain, leg weakness, paraesthesia and urinary dysfunction. The mean time from presentation to health services to definitive treatment was 42.5 days (range 16–74 days). Diagnosis was confirmed with CSF serology for schistosomiasis in all cases. Radiological features on MRI spine included enhancement focused predominantly in the lower thoracic spinal cord in three cases and the conus in one patient. All patients received a minimum of three days of oral praziquantel and high dose steroids. At three-month follow-up, one patient had complete resolution of symptoms and three had residual deficit; one patient was left with urinary and faecal incontinence, another had urinary retention, and the final patient has persistent leg pains and constipation. Conclusion: We observed a marked delay in diagnosis of neuroschistosomiasis in a non-endemic country. We advocate undertaking a thorough travel history, early use of imaging and CSF schistosomal serology to ensure early diagnosis of neuroschistosomiasis in patients presenting with consistent symptoms. If schistosomal diagnostics are not immediately available, presumptive treatment under the guidance of a tropical medicine specialist should be considered to minimize the risk of residual disability. We advocate for consensus guidelines to be produced and reporting to be performed in a uniform way for patients with spinal schistosomiasis.

26 November 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
AWAngus de Wilton
Angus de Wilton
EKEliz Kilich
Eliz Kilich
ZCZain Chaudhry
Zain Chaudhry
LBLucy Ck Bell
Lucy Ck Bell
JGJoshua Gahir
Joshua Gahir
SLSarah A Logan
Sarah A Logan
Objectives To describe a cohort of self-isolating healthcare workers (HCWs) with presumed COVID-19. Design A cross-sectional, single-centre study. Setting A large, teaching hospital based in Central London with tertiary infection services. Participants 236 HCWs completed a survey distributed by internal staff email bulletin. 167 were women and 65 men. Measures Information on symptomatology, exposures and health-seeking behaviour were collected from participants by self-report. Results The 236 respondents reported illness compatible with COVID-19 and there was an increase in illness reporting during March 2020 Diagnostic swabs were not routinely performed. Cough (n=179, 75.8%), fever (n=138, 58.5%), breathlessness (n=84, 35.6%) were reported. Anosmia was reported in 42.2%. Fever generally settled within 1 week (n=110/138, 88%). Several respondents remained at home and did not seek formal medical attention despite reporting severe breathlessness and measuring hypoxia (n=5/9, 55.6%). 2 patients required hospital admission but recovered following oxygen therapy. 84 respondents (41.2%) required greater than the obligated 7 days off work and 9 required greater than 3 weeks off. Conclusion There was a significant increase in staff reporting illness compatible with possible COVID-19 during March 2020. Subsequent serology studies at the same hospital study site have confirmed sero-positivity for COVID-19 up to 45% by the end of April 2020 in frontline HCWs. The study revealed a concerning lack of healthcare seeking in respondents with significant red flag symptoms (severe breathlessness, hypoxia). This study also highlighted anosmia as a key symptom of COVID-19 early in the pandemic, prior to this symptom being more widely recognised as a feature of COVID-19.

12 June 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
Mikaela ColemanMikaela Coleman
Mikaela Coleman
AMA Manyara
A Manyara
CCC J Calderwood
C J Calderwood
AWA de Wilton
A de Wilton
EME I Y Madela
E I Y Madela
CGC L Gregson
C L Gregson
Post-tuberculosis disability impairs quality-of-life, yet chronic functional outcomes for tuberculosis survivors remain under-characterized. This cross-sectional sub-study (2022–2024) estimated Fried frailty phenotype prevalence among adults aged ≥40 years with self-reported prior tuberculosis in South Africa and Zimbabwe, compared with those with no tuberculosis history. Survivor bias was evaluated using historic WHO data. After adjusting for age, sex, education, HIV, diabetes and socioeconomic factors, prior tuberculosis was associated with twice the odds of frailty (OR = 2.06, 95% CI 1.38–3.03, P = .001), and worse survival into older age. As longevity increases in Southern Africa, healthy-ageing interventions for tuberculosis survivors could improve function and survival into older age.

15 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MYMasahiro Yoshida
Masahiro Yoshida
KWKaylee B. Worlock
Kaylee B. Worlock
NHNi Huang
Ni Huang
RLRik G.H. Lindeboom
Rik G.H. Lindeboom
CBColin R. Butler
Colin R. Butler
KMKerstin B. Meyer
Kerstin B. Meyer
While a substantial proportion of adults infected with SARS-CoV-2 progress to develop severe disease, children rarely manifest respiratory complications. Therefore, understanding differences in the local and systemic response to SARS-CoV-2 infection between children and adults may provide important clues about the pathogenesis of SARS-CoV-2 infection. To address this, we first generated a healthy reference multi-omics single cell data set from children (n=30) in whom we have profiled triple matched samples: nasal and tracheal brushings and PBMCs, where we track the developmental changes for 42 airway and 31 blood cell populations from infancy, through childhood to adolescence. This has revealed the presence of naive B and T lymphocytes in neonates and infants with a unique gene expression signature bearing hallmarks of innate immunity. We then contrast the healthy reference with equivalent data from severe paediatric and adult COVID-19 patients (total n=27), from the same three types of samples: upper and lower airways and blood. We found striking differences: children with COVID-19 as opposed to adults had a higher proportion of innate lymphoid and non-clonally expanded naive T cells in peripheral blood, and a limited interferon-response signature. In the airway epithelium, we found the highest viral load in goblet and ciliated cells and describe a novel inflammatory epithelial cell population. These cells represent a transitional regenerative state between secretory and ciliated cells; they were found in healthy children and were enriched in paediatric and adult COVID-19 patients. Epithelial cells display an antiviral and neutrophil-recruiting gene signature that is weaker in severe paediatric versus adult COVID-19. Our matched blood and airway samples allowed us to study the spatial dynamics of infection. Lastly, we provide a user-friendly interface for this data 1 as a highly granular reference for the study of immune responses in airways and blood in children.

24 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TMTiffeney Mann
Tiffeney Mann
JGJames Greenan-Barrett
James Greenan-Barrett
SWSacha Wright
Sacha Wright
ESEllen Steward
Ellen Steward
MNMai Nguyen
Mai Nguyen
RGRishi K. Gupta
Rishi K. Gupta
Background: Biomarkers have been widely proposed as having potential to improve tuberculosis (TB) detection, prediction of progression, and treatment monitoring, but evidence is fragmented and it is unclear which biomarkers have the strongest evidence base. We undertook an umbrella review to synthesise this evidence.Methods: This umbrella review (PROSPERO CRD420251230142) evaluated systematic reviews of biomarkers for three broad TB use-cases: detection of TB disease, prediction of progression to TB disease, and TB treatment monitoring and optimisation. We searched MEDLINE, Web of Science, Global Index Medicus and Cochrane Library for systematic reviews of host- or pathogen-derived biomarkers from January 2018 and appraised review quality using AMSTAR-2. For each biomarker class and use case we summarised the technology readiness, strength of evidence, diagnostic accuracy, extent of independent validation, operational characteristics, and unmet need addressed. We synthesised evidence for each biomarker class qualitatively and quantitatively, against a pre-specified biomarker prioritisation framework.Findings: Forty-five systematic reviews met inclusion criteria: 39 on TB detection, 7 on progression and 6 on treatment monitoring. Nine classes of host- or pathogen-based biomarkers were identified, most commonly host protein, host transcriptomic and host miRNA. For TB detection, evidence was strongest for host protein, host transcriptomic, and pathogen antigen classes, while the immune phenotype, exhaled breath and pathogen DNA/RNA classes were earlier in development, lacking independent validation. Across use cases, estimates of diagnostic accuracy varied widely and were often lower in higher quality studies with clinically relevant populations. In high-quality studies no biomarkers consistently met WHO target product profile thresholds. For TB progression, the strongest evidence was for host transcriptomic, which predicted the short-term risk of TB progression but showed modest performance over longer follow-up intervals. For TB treatment monitoring, evidence to predict clinical outcomes is limited across all classes.Interpretation: Many systematic reviews have been published describing numerous TB biomarkers, especially for the TB detection use case. Robust validation of candidate biomarkers in clinically relevant populations is lacking for many classes. Further prospective head-to-head validation studies are needed to determine which biomarkers have meaningful potential to improve individual and public health outcomes.